Pharmaceutical Distribution Agreement

7.3 CASI makes available to the distributor all documents and invoices necessary during the sale and distribution of the product. CASI provides a delivery voucher containing information about product code, quantity, lot number, production date and expiry date. 4.3 When existing regulatory requirements change and there is disagreement over the interpretation of one aspect of the VPA and/or one of the contracting parties requests a review of these VPAs due to problems or conflicts related to legal or regulatory requirements, the contracting parties agree to review and, if necessary, amend and/or revise the terms of these VPAs. Renegotiations/reviews are considered completed when the contracting parties make a written amendment or supplement to this VPA. 14.10 Conflict with conditions. In the event of a conflict between the terms and conditions of this Agreement and all the conditions that can be set by an order, invoice, verbal agreement or any other means, the terms of this agreement apply. Unless expressly stated otherwise, the terms of this contract apply in the event of a conflict between the terms of this agreement and the terms of one of the exhibitions. “regulatory authority,” any public regulator within an area that participates in the regulation of all aspects of production, sale, distribution, packaging or the use of (s) product (s). 4.2 Correction of the defective product. If Mikah accepts that a batch is a defective product, Mikah will replace the defective product or refund the total amount of all payments, including payments subject to the shipping obligation, made by DRL for that product. If Mikah disagrees with DRL`s finding that this product is a defective product, each party may, after making reasonable efforts to resolve disputes, forward a sample, batch registration and associated documentation of the product to a mutually agreed independent third party, who is an expert or is familiar with the industry, to determine whether the product complies with specifications or is otherwise defective.

The results of the independent part are final and binding on both parties. If such results indicate that the product was defective, Mikah must replace the defective product or refund the total amount of all payments, including shipping costs, made by DRL for that product. Unless the parties have agreed otherwise in writing, the costs of the review and verification are borne by the non-dominant party. 25.1 Changes and amendments are made only by a written endorsement, after consultation and confirmation from all parties. If there is a discrepancy between this agreement and the endorsement, the endorsement replaces the endorsement. “API,” the pharmaceutical active ingredient for the product. 4.4 Commercial Agents. EuroGen asks its sales agents and all other agents, as well as authorized agents and agents, to comply with all applicable laws and regulations regarding the advertising, marketing, distribution and sale of products in the territory. 3.7 Records and financial audit. Mikah maintains records and documents that document the transfer price of each product, and DRL holds all records that document the net sale to the sale of products for a period equal to the period prescribed by applicable laws.

Each party has the right, in two calendar years immediately prior to, after at least ten (10) working days, to send the books and recordings of the other party by an independent external auditor in order to verify the obligations of the other party (for example. B DRL can verify the transfer price and Mikah can review the calculation of the percentage of participation, including all underlying revenue data, as well as calculations of net sales and net earnings).